Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen’s | Enterpreneurship
The Friday approval for the Teva (NYSE: TEVA) drug fremanezumab (Ajovy) came a little earlier than expected; the target date for the FDA decision was Sept. 16. The drug is part of class of drugs called calcitonin gene-related peptides (CGRP). These antibody drugs work by blocking the CGRP protein, which is associated with migraine pain. The Amgen (NASDAQ: AMGN) CGRP drug erenumab (Aimovig) was approved in May.
Amgen’s migraine drug is a once-monthly… Read more »
UNDERWRITERS AND PARTNERS